A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

by Liz Hanson | Feb 20, 2021 | Uncategorized | 0 comments